Freiraum Ventures

Freiraum Ventures is an early-stage venture capital firm based in Munich, Germany, dedicated to backing promising startups across diverse industries. The firm focuses on identifying and supporting entrepreneurial teams with strong business ideas and a clear commitment to growth. They emphasize knowledge and education as key investment criteria, aiming to be the first institutional investor in a company. Freiraum Ventures provides capital ranging from EUR 50,000 to 200,000, with an average ticket size of EUR 100,000, and supports its portfolio companies with coaching and access to the extensive infrastructure of the Strascheg Center for Entrepreneurship (SCE).

Established in 2020, Freiraum Ventures emerged from the Strascheg Center for Entrepreneurship, which is the entrepreneurial hub of the Munich University of Applied Science (MUAS). The fund is notably backed by Prof. Dr. Falk F. Strascheg, a highly experienced and successful venture capitalist in Germany and Europe. This strong institutional backing and affiliation provide Freiraum Ventures with a unique position to nurture early-stage ventures, leveraging academic rigor and practical entrepreneurial support.

The firm's portfolio showcases a broad investment strategy, including companies like ZERØTEC, which focuses on sustainable technology solutions, and ONYX BIOTECH and XENOPATCH in the biotechnology sector. Other notable investments span healthcare (BREATHMENT, PHYSIOFIT, PANTOHEALTH), financial technology (REFINQ), and various software and business services companies such as MODELWISE, SYNSOR, and GET2GERMANY. This diverse range reflects Freiraum Ventures' commitment to a multi-sector approach while maintaining a focus on innovative and scalable business models.

The team at Freiraum Ventures comprises experienced professionals, including Partners David Photien, Prof. Dr. Klaus Sailer, and Prof. Dr. Herbert Gillig, who bring a wealth of knowledge and expertise to their investment decisions and portfolio support. They are complemented by Investment Associate Daniel Rasel and Investment Analyst Mateo Kulis. This team-based approach ensures that portfolio companies receive comprehensive guidance, mentorship, and strategic advice throughout their early-stage development.